Unlike many of his Silicon Valley colleagues who abandoned the life sciences practice for Internet law in the mid- to late ’90s, Kenneth Clark stuck it out with his biotech clients, which were then not as favored by investors as dot-com companies.

Today, the Wilson Sonsini Goodrich & Rosati partner is glad he kept collaborating with biotech firms because partnership transactions are increasingly common — and increasingly valuable.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]